ReviewWorld journal of gastroenterology2009
Alcoholic liver disease and hepatitis C: a frequently underestimated combination.
Review in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 138 citations in OpenAlex.
- Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs.Journal of viral hepatitis · 2020Trial
- Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study.Journal of community health · 2015Trial
- Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection.Addictive behaviors · 2012Trial
- Retrospective Analysis of Diagnostic and Prognostic Value of Serum Glypican-3 in Patients With HCV-Related Cirrhosis With Or Without HCC After Achieving SVR With DAA Treatment.Journal of gastrointestinal cancer · 2026Observational
- Comparison of initial treatments for resectable hepatocellular carcinoma within Milan criteria: an observational study based on a nationwide survey.Annals of surgical treatment and research · 2025Article
- Article
- Toxicity Tolerance in the Carcinogenesis of Environmental Cadmium.International journal of molecular sciences · 2024Review
- Biomarkers of Innate Immunity and Immunological Susceptibility to Viral Infection in Patients with Alcoholic Cirrhosis.Biomedicines · 2024Article
- The Role of Endoplasmic Reticulum Stress Response in Liver Regeneration.Seminars in liver disease · 2023Review
- Alcohol, Inflammation, and Microbiota in Alcoholic Liver Disease.International journal of molecular sciences · 2023Review
- Redox Control of Integrin-Mediated Hepatic Inflammation in Systemic Autoimmunity.Antioxidants & redox signaling · 2022Review
- Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma Molecules.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The History of Alcoholic Liver Disease: From an Unrecognized Disease to One of the Most Frequent Diseases in Hepatology.Journal of clinical medicine · 2021Review
- Non-invasive Biomarkers of Liver Inflammation and Cell Death in Response to Alcohol Detoxification.Frontiers in physiology · 2021Article
- Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy.Toxicology reports · 2021Review
- Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland.Journal of viral hepatitis · 2020Article
- Religious Service Attendance and Deaths Related to Drugs, Alcohol, and Suicide Among US Health Care Professionals.JAMA psychiatry · 2020Article
- Alcohol Use and Ethnicity Independently Predict Antiretroviral Therapy Nonadherence Among Patients Living with HIV/HCV Coinfection.Journal of racial and ethnic health disparities · 2020Article
- Alcohol-induced autophagy via upregulation of PIASy promotes HCV replication in human hepatoma cells.Cell death & disease · 2018Article
- Alcoholic liver disease.Nature reviews. Disease primers · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcoholic liver disease (ALD) and hepatitis C virus (HCV) infection represent, either alone or in combination, more than two thirds of all patients with liver disease in the Western world. This review discusses the epidemiology and combined impact of ALD and HCV on the progression of liver disease. ALD and HCV affect the progression of liver disease to liver cirrhosis and hepatocellular carcinoma (HCC) in a synergistic manner. Thus, the risk for HCC increases five times with a daily alcohol consumption of 80 g; in the presence of HCV it is increased 20-fold, and a combination of both risk factors leads to a more than 100-fold risk for HCC development. Alcohol consumption also decreases the response to interferon treatment which is probably due to a lack of compliance than a direct effect on HCV replication. Several molecular mechanisms are discussed that could explain the synergistic interaction of alcohol and HCV on disease progression. They include modulation of the immune response and apoptosis, increased oxidative stress via induction of CYP2E1 and the hepatic accumulation of iron. Thus, both HCV and alcohol independently cause hepatic iron accumulation in > 50% of patients probably due to suppression of the liver-secreted systemic iron hormone hepcidin. A better understanding of hepcidin regulation could help in developing novel therapeutic approaches to treat the chronic disease in the future. For now, it can be generally concluded that HCV-infected patients should abstain from alcohol and alcoholics should be encouraged to participate in detoxification programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.